Recently, the Breast Cancer Consortium highlighted the necessity to also treat variant in other genes, including among others ATM, CHEK1, and CHEK2, in a similar manner to BRCA alterations, given their important influence on breast cancer development23. This evidence concerns the gene CHEK1 and breast carcinoma.